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Abstract
Systemic sclerosis (SSc) is a multi-system disease characterized by skin ﬁbrosis and visceral disease. Therapy is organ and
pathogenesis targeted. In this review, we describe novel strategies in the treatment of SSc. Utilizing the MEDLINE and the
COCHRANE REGISTRY, we identiﬁed open trials, controlled trials, for treatment of SSc from 1999 to April 2005. We used
the terms scleroderma, systemic sclerosis, Raynaud’s phenomenon, pulmonary hypertension, methotrexate, cyclosporin,
tacrolimus, relaxin, low-dose penicillamine, IVIg, calcium channel blockers, losartan, prazocin, iloprost, N-acetylcysteine,
bosentan, cyclophosphamide, lung transplantation, ACE inhibitors, anti-thymocyte globulin, and stem cell transplantation.
Anecdotal reports were omitted.
Methotrexate, cyclosporin, tacrolimus, relaxin, low-dose penicillamine, and IVIg may be beneﬁcial in improving the skin
tightness in SSc. Calcium channel blockers, the angiotensin II receptor type 1 antagonist losartan, prazocin, the prostacyclin
analogue iloprost, N-acetylcysteine and the dual endothelin-receptor antagonist bosentan may be beneﬁcial for Raynaud’s
phenomenon. Epoprostenol and bosentan are approved for therapy of pulmonary hypertension (PAH). Other options under
investigation include intravenous or aerolized iloprost. Cyclophosphamide (CYC) pulse therapy is effective in suppressing
active alveolitis. Stem cell and lung transplantation is a viable option for carefully selected patients. Renal crisis can be
effectively managed when hypertension is aggressively controlled with angiotensin converting enzyme (ACE) inhibitors.
Patients should continue taking ACE inhibitors even after beginning dialysis in hope of discontinuing dialysis. Anti-
thymocyte globulin and mycophenolate mofetil appear safe in SSc. The improvement in skin score and the apparent stability
of systemic disease during the treatment period suggest that controlled studies of these agents are justiﬁed. Stem cell
transplantation is under investigation for severe disease. Novel therapies are currently being tested in the treatment of SSc
and have the potential of modifying the disease process and overall clinical outcome. The evaluation of these studies is still a
difﬁcult process.
Keywords: Systemic sclerosis, bosentan, epoprostenol, IVIg, ACE inhibitors, stem cell transplantation
Introduction
Systemic sclerosis (SSc) is a multi-system disease
characterized by skin ﬁbrosis and visceral disease. The
pathophysiology includes vascular damage, ﬁbroblast
proliferation, collagen production and activation of
the immune system. Clinical manifestations include
thickening of the skin, Raynaud’s phenomenon,
pulmonary artery hypertension (PAH) and pulmonary
ﬁbrosis, renal disease and involvement of other
visceral organs. There is no single medication for
the constellation of manifestations, rather therapy is
organ and pathogenesis targeted (Table I). In this
review, we describe novel strategies in the treatment of
SSc.
Skin involvement and early diffuse disease
Early diffuse SSc has no proven treatment. The
efﬁcacy of methotrexate (MTX) in improving the skin
and other disease parameters was evaluated in 71
patients with early diffuse SSc of , 3 years’ duration
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G. Zandman-Goddard et al. 166that were enrolled in a multicenter, randomized,
placebo-controlled, double-blind trial (Pope et al.
2001). Thirty-ﬁve patients were treated with MTX
(the maximum dose was 15mg/week orally) and 36
with placebo for 12 months. At baseline, there were no
statistically signiﬁcant differences in skin scores,
carbon monoxide diffusing capacity (DLCO), phys-
ician global assessment, or other secondary outcome
measurements between the 2 treatment groups. At
study completion, results slightly favored the MTX
group when compared to placebo for the modiﬁed
Rodnan skin score (p , 0.17) and for DLCO (p ,
0.2). In addition, physician global assessment results
favored MTX (P , 0.035), whereas patient global
assessment did not differ signiﬁcantly between groups.
When between-group differences for changes in scores
from baseline to 12 months were examined using
intent-to-treat methodology, MTX appeared to have a
favorable effect on skin scores (p , 0.009), but
differences in the degree of change in the DLCO and
physician global assessment were not signiﬁcant.
Although the results of this trial demonstrated a
trend in favor of MTX versus placebo in the treatment
of early diffuse SSc, the between-group differences
were small and the power to rule out false-negative
results was only 50%. These ﬁndings did not provide
evidence that MTX is signiﬁcantly effective in the
treatment of early diffuse SSc.
Cyclosporinandtacrolimusareimmunomodulatory
drugsthatactpredominantlyonTcells.Improvements
in certain manifestations, particularly skin tightness,
have been observed in a number of patients with SSc
treated with these drugs. However, to date there have
been no reportsoftheir useinaroutine clinical setting.
In one study, patients attending clinical immunology
clinicswhohadreceivedcyclosporinand/or tacrolimus
were identiﬁed. Details of their treatment, including
drug dosage, duration and response to treatment, side
effects and reasons for withdrawal, were recorded.
Sixteen patients had been given cyclosporin and 13 of
thosehadbeentreatedforskintightness.Halfnoticeda
signiﬁcant softening of their skin whilst on treatment,
and resolution was observed in all four of the patients
treated for digital vasculitis. Adverse effects were
common and dose-limiting, and contributed to with-
drawalin12outof13patients.Eightpatientshadbeen
treated with tacrolimus; two of these had stopped
the drug because of progression of their disease, one
developed diarrhea, prompting withdrawal, one
stopped tacrolimus following improvement, and four
remained on the drug. Side effects had occurred in
three patients. Improvements in skin occurred in
approximatelyhalfofallcasesofSSctreatedwitheither
cyclosporin or tacrolimus, suggesting a beneﬁcial
effect. Side effects, especially hypertension, are
common with cyclosporin and often necessitate with-
drawal. Adverse effects are also observed with
tacrolimus, but in the small cohort so far treated,
only one patient had stopped the drug for this reason
(Morton and Powell 2000).
Relaxin is a pregnancy-related hormone that has
tissue remodeling and antiﬁbrotic effects. It inhibits
endothelin-1, inhibits angiotensin II, and increases
collagenase production. The efﬁcacy, safety and dose-
response effect of recombinant human relaxin in
patients with SSc was assessed in a multicenter,
parallel-group, randomized, double-blind, placebo-
controlled trial (Seibold et al. 2000). Sixty-eight
patients who had had stable, diffuse SSc (moderate to
severe) for less than 5 years were enrolled. Recombi-
nant human relaxin, 25 or 100mg/kg of body weight
per day, or placebo administered by continuous
subcutaneous infusion over 24 weeks was adminis-
tered. Modiﬁed Rodnan skin score was the primary
efﬁcacy measure. Secondary measurements were
pulmonary function, the health assessment question-
naire (HAQ), and other measures of SSc that reﬂected
ﬁbrosis. Patients who received 25mg/kg of recombi-
nant human relaxin per day had signiﬁcantly lower
skin scores than those who received placebo
(p ¼ 0.040). Similar trends were noted in other
outcome measures, including forced vital capacity,
measures of oral aperture and hand extension,
functional status, and global assessment. Patients
who received 100mg/kg of relaxin per day did not
differ from those who received placebo. Drug-related
adverse events included menometrorrhagia, reversible
anemia, and complications of the subcutaneous drug
administration system (site irritation and local infec-
tion). Following 24 weeks of recombinant human
relaxin at a dose of 25mg/kg/d, there was reduced skin
thickening, improved mobility, and improved function
in patients with moderate to severe disease.
The hypothesis that SSc patients taking high-dose
D-penicillamine (D-Pen) would have a greater soft-
ening of skin, lower frequency of renal crisis, and
better survival than patients taking low-dose D-Pen
was tested in 134 SSc patients with early (#18
months) diffuse cutaneous SSc in a 2-year, double-
blind, randomized comparison of high-dose D-Pen
(750–1000mg/day) versus low-dose D-Pen (125mg
every other day) (Clements et al. 1999). All 134
patients were followed up for a mean ^ SD of
4.0 ^ 1.1 years to assess the frequencies of new-
onset SSc renal crisis and mortality. The conclusion of
the study was that the course of the skin score and the
frequencies of SSc renal crisis and mortality in the
high-dose D-Pen group were not different from those
in the low-dose D-Pen group. Eighty percent of the
adverse event-related withdrawals occurred in the
high-dose D-Pen patients. Although this study did not
answer the question of whether low-dose D-Pen is
effective, it did suggest that there is no advantage to
using D-Pen in doses higher than 125 every other day.
The response of SSc patients to treatment with
intravenousimmunoglobulin(IVIg)wasdemonstrated
New therapeutic strategies for SSc 167in 3 patients with progressive and rapidly deteriorating
disease (mainly affecting the skin). The patients were
planned to receive six monthly courses of high-dose
IVIg (2g/kg body weight over 5 days/course). All had a
thorough physical examination, clinical evaluation by
the modiﬁed Rodnan total skin thickness score, and
measurement of the titers of PM-Scl antibodies before
and after the treatment, and before and after each
treatmentcourse.Twoofthethreepatientsreceivedsix
IVIg courses as planned and no adverse effects or
disease progression occurred during the therapy. The
third patient received three courses, after which he
developedrenalfailureandlaterdiedofsepsis.Allthree
patients had a signiﬁcant decrease in their skin score
after the treatment compared to that before the
treatment. No modiﬁcation of PM-Scl antibody titers
was noted in any patient (Levy et al. 2000). IVIg may
havearoleinthetreatmentofSScpatientswithrapidly
deteriorating skin disease. The speciﬁc indications, as
well as the safety of this treatment, should be further
researched.
Eight patients with excess ﬁbrotic reaction in the
course of diverse diseases were analysed; a tendency
that reverted with different IVIg treatment options.
Three patients had SSc as their main feature. Fibrotic
excess was reduced in all the patients by IVIg
treatment. In ﬁve patients, the disease as a whole
beneﬁted from the infusion of immunoglobulins. IVIg
may enhance resorption of ﬁbrosis and promote
healing in patients with ﬁbrotic associated disorders
(Amital et al. 2003). In another study, 15 SSc patients
were treated with high dose IVIg (2g/kg/course) for
3–6 monthly courses. Five patients had limited
disease and 10 patients had diffuse disease. Efﬁcacy
was determined by a change in the modiﬁed Rodnan
index and the HAQ quality of life score. The mean
decrease in the skin score was signiﬁcant (p , 0.001).
A signiﬁcant improvement in the patients’ well-being
and quality of life was reﬂected by a decrease in the
HAQ score (p ¼ 0.03) (Levy et al. 2004).
Raynaud’s phenomena/pulmonary hypertension
Most patients with SSc have Raynaud’s phenomenon
(RP), which is often more severe than idiopathic RP.
A meta-analysis to determine the efﬁcacy of calcium-
channel blockers for the treatment of RP in SSc was
performed (Thompson et al. 2001). Twenty-nine
studies were found, of which 8 randomized controlled
trials were eligible for inclusion. The total number of
patients included was small (n ¼ 109). Most trials
included primary and secondary RP. The weighted
meandifferenceofallcalcium—channelblockersversus
placebo (6trials) and of nifedipine alone versusplacebo
(5 trials) for the reduction in the frequency of ischemic
attacks over a 2-week period was 28.31 (95%
conﬁdence interval [95% CI] 215.71, 20.91) and
210.21 (95% CI 220.09, 20.34), respectively.
The standardized mean difference of all calcium-
channel blockers versus placebo (3 trials) and of
nifedipine alone versus placebo (2 trials) for the
reduction in the severity of ischemic attacks were
20.69 (95% CI 21.21, 20.17) and 20.99 (95% CI
21.74,20.24),respectively.Theconclusionswerethat
calcium-channelblockersforRPinSSchavebeentested
in several small clinical trials and appear to lead to
moderate clinical improvement in both the frequency
and the severity of ischemic attacks. Further large,
randomized controlled trial needs to be conducted.
The efﬁcacy and tolerability of losartan, an
angiotensin II receptor type 1 antagonist and
nifedipine for the treatment of primary and secondary
RP were compared in a pilot study (Dziadzio et al.
1999). In a randomized, parallel-group, controlled
trial, 25 patients with primary RP or 27 RP patients
secondary to SSc were allocated to receive 12 weeks’
treatment with either losartan (50mg/day) or nifedi-
pine (40mg/day). Primary outcome variables were the
severity and frequency of RP episodes and ﬁndings on
vascular measurements, including thermography and
laser Doppler ﬂowmetry. Serum levels of soluble
adhesion molecules, endothelin 1, ﬁbrinogen, von
Willebrand factor, and procollagen type I N-terminal
propeptide (PINP) were also measured. There was a
reduction in the severity of RP episodes following
treatment with losartan and with nifedipine, but this
effect was greater in the losartan arm of the study
(P , 0.05): Episode frequency was reduced only in
the losartan group (P , 0.01 versus baseline).
Symptomatic improvement was associated with a
signiﬁcant reduction in soluble vascular cell adhesion
molecule 1 and PINP (P , 0.01). Subgroup analysis
suggested that although these biochemical changes
occurred mainly in SSc patients, the clinical beneﬁt
was greater in the primary RP group. This study
conﬁrmed the tolerability of short-term treatment of
RP with losartan, and its clinical beneﬁt. Further
evaluation of this drug as a long-term treatment for
SSc-associated RP should be considered, since it may
have additional disease-modifying potential.
The effects and toxicity of prazosin, an alpha-1
inhibitor, compared to placebo proposed for the
treatment of RP in SSc was evaluated (Thompson
et al. 2001) Prazosin was found in two randomized
controlled cross-over trials (n ¼ 40) to be more
effective than placebo in the treatment of RP
secondary to SSc. However, the positive response
was modest and side effects were not rare in those
taking prazosin. Prazosin is modestly effective in the
treatment of RP secondary to SSc.
Epoprostenol is a potent, short acting vasodilator
and inhibitor of platelet aggregation produced by
vascular endothelium. Epoprostenol is an effective
vasodilator, reduces pulmonary resistance and platelet
aggregation, increases cardiac output and demon-
strates favorable effects on vascular remodulation.
G. Zandman-Goddard et al. 168Epoprostanol improved quality of life and survival in
patients with PAH (Badesch et al. 2000, Sitbon et al.
2002).
Iloprost is a chemically stable synthetic analogue of
prostacyclin (prostacyclin agonist) that decreases
pulmonary vascular resistance. Iloprost is longer
acting than epoprostenol with vasodilatory properties
and platelet inhibitory effects. The effects and toxicity
of prostacyclin analogues together with other agents
proposed for the treatment of RP in SSc utilizing the
Cochrane controlled trials register were analyzed
(Pope et al. 2000). All randomized controlled trials
comparing prostaglandin analogues versus placebo
were eligible if they reported clinical outcomes within
the start of therapy. Seven randomized trials and 332
patients were included. Five trials compared intrave-
nous iloprost and one trial studied oral iloprost and
oral cisaprost. In some trials, various doses of iloprost
were used. Due to different efﬁcacies of intravenous
iloprost, oral iloprost and oral cisaprost, the overall
efﬁcacy of these drugs was somewhat diluted.
Intravenous iloprost is effective in the treatment of
RP secondary to SSc at decreasing the frequency and
severity of attacks and preventing or healing digital
ulcers. The effect seems to be prolonged after the
intravenous infusion is given. Oral iloprost may have a
lower efﬁcacy than intravenous iloprost. However,
cisaprost has minimal or no efﬁcacy when given orally
for the treatment of RP secondary to SSc.
Inhaled aerosolized iloprost, a stable prostacyclin
analogue, has been considered a selective pulmonary
vasodilator in the management of PAH (Olschewski
et al 2000). One study assessed the efﬁcacy of inhaled
iloprost in the treatment of life-threatening PAH in an
open, uncontrolled, multi-center study in intensive
care units and PAH clinics at six university hospitals in
Germany. Nineteen patients who had progressive
right-heart failure despite receiving maximum con-
ventional therapy (12 with primary PAH, 3 with PAH
related to collagen vascular disease without lung
ﬁbrosis, and 4 with secondary PAH) were enrolled
into the study. The patients were treated with inhaled
iloprost, 6–12 times daily (50–200mg/d). Right-heart
catheterization and distance walked in 6min at
baseline and after 3 months of therapy were evaluated.
During the ﬁrst 3 months of therapy, New York Heart
Association (NYHA) functional class improved in 8
patients and was unchanged in 7 patients. Four
patients died, 3 of right-heart failure and 1 of sepsis.
The acute hemodynamic response to inhaled iloprost
was predominant pulmonary vasodilatation with little
systemic effect at baseline and at 3 months (data
available for 12 patients). Hemodynamic variables
were improved at 3 months, and the distance walked
in 6min improved by 148m (p ¼ 0.048). Of the
15 patients who continued to use inhaled iloprost,
8 discontinued therapy; four had lung transplantation,
1 switched to intravenous prostacyclin therapy,
and 3 died. Seven patients still received inhaled
iloprost at 536 ^ 309 days; at a mean dosage of
164 ^ 38 mg/d. Inhaled iloprost may offer a new
therapeutic option for improvement of hemodynamics
and physical function in patients with life-threatening
PAH and progressive right-heart failure that is
refractory to conventional therapy.
Continuous subcutaneous infusion of treprostinil
(initiated at 1.25ng/kg/min, and titrated upward),
a stable prostacyclin analogue was evauated for
treating PAH in patients with connective tissue disease
(CTD) in a randomized, double-blind, placebo-
controlled, prospective trials in a subset of 90 patients
with PAH and CTD, including systemic lupus
erythematosus (SLE), diffuse and limited SSc, and
mixed CTD/overlap syndrome. At baseline, most
patients had NYHA class III symptoms. Continuous
subcutaneous infusion of treprostinil in patients with
PAH associated with CTD improved exercise
capacity, symptoms of PAH, and hemodynamics
(Oudiz et al. 2004).
Beraprost is the ﬁrst orally active prostacyclin
analogue. In the ﬁrst of two randomized controlled
trials, beraprost increased exercise capacity in patients
with idiopathic PAH, with no signiﬁcant changes in
subjects with associated conditions. Hemodynamics
did not change signiﬁcantly, and no difference in
survival was detected between the two treatment
groups. The second study, showed that beraprost-
treated patients had less disease progression at 6
months and conﬁrmed the results of the previous trial.
However, this improvement was no longer present at 9
or 12 months (Badesch et al. 2004).
The objective of another study was to assess the
effect of beraprost sodium on pulmonary function in
patients with SSc. Seventeen patients, with SSc and
DLCO of less than 95%, received beraprost sodium
for at least 12 months. DLCO levels in patients with
SSc improved after the administration of beraprost
sodium, probably due to the decrease in pulmonary
vascular resistance accompanied by increased cardiac
output (Matsukawa et al. 2002).
Endothelin 1 (ET1), a powerful endogenous
vasoconstrictor and mitogen, might be a cause of
pulmonaryhypertension.ET1causesvasoconstriction
as well as endothelial activation, cell proliferation and
ﬁbrosis. The dual endothelin receptor antagonist
bosentan is the ﬁrst oral therapy approved for the
treatmentofpulmonaryhypertension.Amongpatients
withprimaryPAHorPAHrelatedtoSSc,randomized,
double blind, placebo-controlled studies have demon-
strated that bosentan therapy (62.5–250mg twice
daily) improves hemodynamics, exercise capacity and
functional class (Channick et al. 2001, Rubin et al.
2002).Inaddition,adelayintimetoclinicalworsening
was demonstrated in bosentan-treated patients
compared with placebo, with clinical beneﬁts
maintained for up to 28 weeks (Rubin et al. 2002).
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improvement in functional class persisted for up to
one year (Sitbon et al. 2003). A recent study carries
these resultsevenfurther by administering bosentan as
a ﬁrst-line therapy, as well as evaluating long-term
survival. In a long term, observational manner, ﬁrst-
line therapy with bosentan (125–250mg daily),
followed by other therapy if needed, improved survival
inpatientswithprimaryPAH.Thesurvivalattwoyears
was 89% compared to the predicted survival of 57%.
Those patients with more advanced symptoms (func-
tional class IV), and lower exercise tolerance had a
worse outcome (McLaughlin et al. 2005). This last
study does not refer to patients with secondary PAH,
buttherearepreviousstudiesshowingsimilarresultsto
treatment with bosentan among patients with primary
or secondary PAH. The long term survival of SSc
patients with PAH treated with bosentan is yet to be
determined.
Phosphodiesterase type 5 (PDE5) inhibition has
been proposed for the treatment for PAH. One study
compared adding sildenaﬁl, a PDE5 inhibitor to
bosentan. Twenty-six patients with PAH, idiopathic or
associated with CTD, functional class III, were
randomized in a double-blind fashion to receive
sildenaﬁl (50mg twice daily for 4 weeks, then 50mg
three times daily) or bosentan (62.5mg twice daily for
4 weeks, then 125mg twice daily) over 16 weeks.
Measurements of efﬁcacy included changes in right
ventricular (RV) mass, 6-min walk distance, cardiac
function, brain natriuretic peptide, and Borg dyspnea
index. When analyzed by intention to treat, there were
no signiﬁcant differences between the two treatment
groups. One patient on sildenaﬁl died suddenly.
Sildenaﬁl added to conventional treatment reduces
RV mass and improves cardiac function and exercise
capacity in patients with severe PAH. Safety monitor-
ing is important until more experience is obtained
(Lee et al. 2005).
To date, 8 hemodynamic studies and 12 clinical
trials (1 retrospective, 3 double-blind, 8 open-label)
were performed to assess the efﬁcacy of sildenaﬁl for
PAH (Wilkins et al. 2005). Sildenaﬁl reduced PAH
and pulmonary vascular resistance/peripheral vascular
resistance index and tended to increase cardiac
output/cardiac index compared with baseline. Silde-
naﬁl was comparable to nitric oxide and at least as
effective as iloprost or epoprostenol in terms of its
pulmonary vasoreactivity. Combination therapy with
iloprost, nitric oxide, or epoprostenol resulted in
enhanced and prolonged pulmonary vascular effects.
Clinical trials suggest that sildenaﬁl improves exercise
tolerance and NYHA functional class, but large,
randomized controlled trials are needed to conﬁrm
these ﬁndings. Overall, sildenaﬁl was well tolerated.
The efﬁcacy and tolerability of N-acetylcysteine
(NAC) in patients with RP secondary to SSc was
assessed in 22 patients in a multicenter, open clinical
trial lasting 11 weeks and conducted in winter (Sambo
et al. 2001). Primary outcome measures were
frequency and severity of RP attacks, and number of
digital ulcers. Secondary outcome measure was
improvement in digital cold challenge test assessed
by photoelectric plethysmography. Patients received a
continuous 5 day intravenous infusion of NAC
starting with a 2h loading dose of 150mg/kg
subsequently adjusted to 15mg/kg/h. All 22 patients
completed the ﬁve-day infusion and 20 of them the
post-treatment follow-up. Both frequency and severity
of RP attacks decreased signiﬁcantly compared to
pretreatment values. Active ulcers were signiﬁcantly
less numerous at all follow-up visits. The mean
recovery time improved measured by the cold
challenge test. Side effects were minor, easily
controlled, and reversible. N-acetylcysteine appears
to be safe for the treatment of RP secondary to SSc
and the preliminary data warrant further controlled
studies.
Fibrosing alveolitis/pulmonary ﬁbrosis
Pulmonary ﬁbrosis and PAH have become the most
common causes of death in SSc. Consequently, the
early diagnosis and treatment of pulmonary ﬁbrosis is
essential to improve morbidity and mortality in SSc
patients.The prompt diagnosis of ﬁbrosing alveolitis is
imperative. There are some trials on the combination
of cyclophosphamide (CYC) (IV or oral) and
prednisone. In one study of 16 SSc patients with
alveolitis, 8 patients were treated with monthly IV
CYC pulse therapy (750mg/m
2) for 12 months;
the other 8 patients were treated with oral CYC
(2–2.5mg/kg/day) for the same period. All patients
received concurrently prednisone (10mg/day).
Pulmonary function tests and high-resolution lung
CT (HRCT) scans were performed before therapy
and at 6 and 12 months. The results indicated that
intravenous CYC pulse therapy was effective in
suppressing active alveolitis. Although in this study it
was not possible to compare pulse therapy with oral
therapy because of the different pattern seen on high-
resolution lung CT between the two groups, it seems
that oral therapy was also effective in suppressing
active alveolitis. Neither regimen improved pulmon-
ary involvement when the reticular appearance
indicating ﬁbrosis predominated over the ground
glass appearance on high resolution lung CT. Hence,
it was concluded that either pulse or oral CYC therapy
may improve the outcome of SSc patients with active
alveolitis (Davas et al. 1999).
In another study, 14 consecutive SSc patients with
lung involvement were treated with 6 pulses of IV
methylprednisolone (10mg/kg) and IV CYC
(15mg/kg) given at 3–4 weekly intervals and HRCT
scans and lung function tests were performed at
baseline and after the 6th pulse to assess the efﬁcacy of
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signiﬁcantly by 35%. HRCT scan scores improved
signiﬁcantly. Twelve of 13 patients experienced either
improvement or stabilization of the HRCT score.
Median DLCO and lung volumes remained stable
during the ﬁrst 12 months. However, after a median
follow-up of 26 months, 67% of patients experienced
deterioration in DLCO. The treatment was safe and
well tolerated. While the IV regimen stabilized lung
disease, deterioration in lung function occurred in the
majority of patients upon discontinuation of therapy.
The rate of deterioration of DLCO may be a useful
marker for determining the intensity of treatment
(Grifﬁths et al. 2002). Another study on 23 patients
showed limited efﬁcacy of IV CYC and prednisone for
alveolitis. All patients received IV CYC (1000mg/m
2
of body surface monthly for 6 months) and oral
prednisone (25mg daily for the ﬁrst month and
subsequently 5mg daily of maintenance dosage for the
remaining 5 months). At the end of the study, 8
patients were stable and 5 patients had a diffusion of
the ground-glass to other segments (Giacomelli et al.
2002).
The combination of IV CYC with high dose
prednisone (1mg/kg/day for 4 weeks, then reducing
the prednisone by 5mg/day on alternating days each 2
weeks) seems to be more efﬁcacious than with low
dose prednisone (, 10mg/day) in an open label study
in 28 SSc patients with ﬁbrosing alveolitis. In the high
dose steroid group, at 12 months there was signiﬁcant
improvement in the percentage of “ground glass”
parenchymal lung involvement, as well as in the
percentage of predicted FVC, the percentage of
predicted DLCO, the percentage of skin involvement,
and the severity of dyspnea. Substantial improvement
was seen as early as 6 months (Pakas et al. 2002).
Low-dose IV CYC has been shown to be efﬁcacious in
severe SLE with renal involvement (Houssiau et al.
2002). The aim of one trial was to test the safety of
low-dose IV CYC in 8 patients with SSc. The patients
were studied at baseline and after 6 months’
intravenous CYC treatment (500mg pulses at 2–4
week intervals). The therapy was well tolerated
overall. No patient discontinued treatment because
of side effects. Leukopenia, premature ovarian failure,
hemorrhagic cystitis, microscopic hematuria and liver
toxicity were never detected. Further studies are
needed to assess both the efﬁcacy and the long-term
safety of the low-dose protocol (D’Angelo et al. 2003).
Lung transplantation in nine patients with SSc
related end-stage lung disease was performed (Rosas
et al. 2000). Patient characteristics included 6 with
limited and 3 with diffuse SSc (seven were females).
Pulmonary ﬁbrosis was present in 78% and pulmon-
ary hypertension in 44%. When compared to a similar
group of transplant patients with non-scleroderma
lung disease (primary pulmonary ﬁbrosis), there was
no signiﬁcant difference in post-transplant survival at
four years, mean annual incidence rate for acute
rejection, and infection, or serum creatinine. Lung
transplantation is a viable option for carefully selected
patients with scleroderma related lung disease.
Gastrointestinal involvement
Chronic intestinal pseudo-obstruction (CIPO) is a
rare syndrome that may occur in association with
scleroderma. Effective management is a major
challenge. Treatment with subcutaneous octreotide
in 3 patients was efﬁcacious in the treatment of
digestive symptoms in CIPO (Perlemuter et al. 1999).
I n2o ft h e3c a s e s ,p r e v i o u st r e a t m e n tw i t h
medications that enhance gastric motility including
domperidone, cisapride, or erythromycin had been
unsuccessful. All 3 patients underwent a regimen of
oral antibiotics along with octreotide to stimulate
small bowel motility. The effects of octreotide were
evident within 48h after the ﬁrst injection in all
patients. In 2 patients, the efﬁcacy seemed to decrease
after 1 week and 6 months respectively, but increasing
the dosage led to another remission. CIPO in SSc is a
severe condition that can evolve regardless of the
underlying disease activity. Octreotide appears to be
efﬁcacious in improving both clinical symptoms and
manometric patterns. When its therapeutic effect
diminishes, increasing the dosage can be useful.
Renal crisis
Although scleroderma renal crisis, a complication of
SSc, can be treated with angiotensin-converting
enzyme (ACE) inhibitors, its long-term outcomes
are not known. In a prospective observational cohort
study, 145 patients with SSc renal crisis who received
ACE inhibitors and 662 patients with SSc who did not
have renal crisis were evaluated (Steen and Medsger
2000). Among patients with renal crisis, the four
outcomes studied were no dialysis, temporary dialysis,
permanent dialysis and early death. Demographic,
clinical, and laboratory datawere compared to identify
risk factors for speciﬁc outcomes. Follow-up was 5–
10 years. Sixty-one percent of patients with renal crisis
had good outcomes (55 received no dialysis, and 34
received temporary dialysis); only 4 of these (4%)
progressed to chronic renal failure and permanent
dialysis. More than half of the patients who initially
required dialysis could discontinue it 3–18 months
later. Survival of patients in the good outcome group
was similar to that of patients with diffuse SSc who did
not have renal crisis. Some patients (39%) had severe
outcomes (permanent dialysis or early death). Renal
crisis can be effectively managed when hypertension is
aggressively controlled with ACE inhibitors. Patients
should continue taking ACE inhibitors even after
beginning dialysis in hopes of discontinuing dialysis.
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The safety and efﬁcacy of anti-thymocyte globulin
(ATG) followed by mycophenolate mofetil (MMF)
was assessed in a pilot study of 13 patients with recent-
onset diffuse SSc (Stratton et al. 2001). Patients
received ATG for 5 days, followed by MMF for 12
months. Adverse events, scleroderma skin score, hand
contractures, scleroderma functional assessment,
pulmonary function studies, echocardiogram and
plasma creatinine concentration were recorded.
Mean skin score decreased during the study
(P , 0.01). Hand contractures worsened during the
study. Mean measurements of systemic disease
remained stable. One patient died after a scleroderma
renal crisis. Five patients developed serum sickness
after ATG treatment, but this was controlled by
corticosteroid therapy. MMF therapy was well
tolerated. ATG and MMF appear safe in SSc. The
improvement in skin score and the apparent stability
of systemic disease during the study period suggest
that controlled studies of these agents are justiﬁed.
Stem cell transplantation
Recent developments in haemopoietic stem cell
transplantation (HSCT) permit the application of
profound immunosuppression, followed by HSCT, or
rescue, to autoimmune diseases such as SSc. The
EBMT/EULAR report describes the longer outcome
of patients originally described in addition to newly
recruited cases. Only patients with SSc, treated by
HSCT in European phase I–II studies from 1996 to
2002, with more than 6 months of follow up were
included. Transplant regimens were according to the
international consensus statements. Repeated evalu-
ations analysed complete, partial, or non-response
and the probability of disease progression and survival
after HSCT. Among 57 patients aged 40 (9.1–68.7)
years, the skin scores improved at 6 (n ¼ 37 patients),
12 (n ¼ 30), 24 (n ¼ 19), and 36 (n ¼ 10) months
after HSCT (p , 0.005). After 22.9 (4.5–81.1)
months, partial (n ¼ 32) or complete response
(n ¼ 14) was seen in 92% and non-response in 8%
of 50 observed cases and 35% of the patients with
initial partial or complete response relapsed within 10
(2.2–48.7) months after HSCT. The transplant
related mortality was 8.7%. Deaths related to
progression accounted for 14% of the 23% total
mortality rate. At 5 years, progression probability was
48% and the projected survival was 72%. This
EBMT/EULAR report showed that response in two
thirds of the patients after HSCTwas durable with an
acceptable transplant mortality rate. Based on these
results, prospective, randomised trials are proceeding.
(Farge et al. 2004). A recent study analyzed
hematopoietic and immune reconstitution after auto-
logous HSCT in 7 patients with SSc. B and T
lymphocyte populations remained disturbed for at
least 1 year after HSCT in SSc patients, which may
reﬂect the persistence of an underlying disease
mechanism (Farge et al. 2005).
In conclusion, SSc is a diversiﬁed disease with
therapy targeted to a speciﬁc organ or mechanism of
disease. The rarity of the disease precludes large
control studies for evidence-based treatment. How-
ever, novel strategies are under investigation and may
be an option for therapy.
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